The results of SURMOUNT-1, the first phase 3 trial with the novel GIP/GLP-1 receptor agonist tirzepatide for obesity, is discussed by Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) as well as key data on remission, a key theme at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:Â
- What were the key clinical trial highlights presented at the 82nd ADA meeting? (0:23)
- The topline results of the groundbreaking SURMOUNT-1 study were presented at this year’s meeting. What are the potential implications of these findings for treating obesity, prediabetes, and type 2 diabetes? (1:53)
- Remission was an important theme at this year’s meeting, can you highlight the key presentations discussing remission in type 2 diabetes and their findings? (3:43)
Disclosures: Osama Hamdy is a consultant for Abbott Nutrition and Sanofi Aventis, has received grant/research support from Eli Lilly, National Dairy Council and Novo-Nordisk. Osama Hamdy is on the advisory Board for L-Neutra, Nemaura and Twin Health and is a major stock shareholder in Healthimation Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
